[HTML] plos.org

[HTML][HTML] Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands

J Stevanović, M Pompen, HH Le, MH Rozenbaum… - PLoS …, 2014 - journals.plos.org
Background Stroke prevention is the main goal of treating patients with atrial fibrillation (AF).
Vitamin-K antagonists (VKAs) present an effective treatment in stroke prevention, however …
被引用次数：40 相关文章
[PDF] academia.edu

[PDF][PDF] Economic Evaluation of Apixaban for the Prevention of Stroke in Non

J Stevanovic, M Pompen, HH Le, MH Rozenbaum… - 2014 - academia.edu
Background: Stroke prevention is the main goal of treating patients with atrial fibrillation (AF).
Vitamin-K antagonists (VKAs) present an effective treatment in stroke prevention, however …
[HTML] nih.gov

[HTML][HTML] Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands

J Stevanović, M Pompen, HH Le, MH Rozenbaum… - PLoS ONE, 2014 - ncbi.nlm.nih.gov
Background Stroke prevention is the main goal of treating patients with atrial fibrillation (AF).
Vitamin-K antagonists (VKAs) present an effective treatment in stroke prevention, however …
[PDF] researchgate.net

[PDF][PDF] Economic Evaluation of Apixaban for the Prevention of Stroke in Non

J Stevanovic, M Pompen, HH Le, MH Rozenbaum… - 2014 - researchgate.net
Background: Stroke prevention is the main goal of treating patients with atrial fibrillation (AF).
Vitamin-K antagonists (VKAs) present an effective treatment in stroke prevention, however …
[PDF] scienceopen.com

[PDF][PDF] Economic Evaluation of Apixaban for the Prevention of Stroke in Non

J Stevanovic, M Pompen, HH Le, MH Rozenbaum… - 2014 - scienceopen.com
Background: Stroke prevention is the main goal of treating patients with atrial fibrillation (AF).
Vitamin-K antagonists (VKAs) present an effective treatment in stroke prevention, however …

Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands.

J Stevanović, M Pompen, HH Le… - PLoS …, 2014 - search.ebscohost.com
Background: Stroke prevention is the main goal of treating patients with atrial fibrillation (AF).
Vitamin-K antagonists (VKAs) present an effective treatment in stroke prevention, however …

Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands

J Stevanović, M Pompen, HH Le, MH Rozenbaum… - PLOS ONE, 2014 - ideas.repec.org
Background: Stroke prevention is the main goal of treating patients with atrial fibrillation (AF).
Vitamin-K antagonists (VKAs) present an effective treatment in stroke prevention, however …

[引用][C] Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands

J Stevanović, M Pompen, HH Le… - PLoS …, 2014 - ui.adsabs.harvard.edu
Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial
Fibrillation in the Netherlands - NASA/ADS Now on home page ads icon ads Enable full ADS …

Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands

J Stevanović, M Pompen, HH Le… - PLOS …, 2014 - econpapers.repec.org
Background: Stroke prevention is the main goal of treating patients with atrial fibrillation (AF).
Vitamin-K antagonists (VKAs) present an effective treatment in stroke prevention, however …

Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands

J Stevanovic, M Pompen, HH Le, MH Rozenbaum… - PLoS ONE, 2014 - research.rug.nl
BACKGROUND: Stroke prevention is the main goal of treating patients with atrial fibrillation
(AF). Vitamin-K antagonists (VKAs) present an effective treatment in stroke prevention …